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Abstract
Background: Position emission tomography (PET) imaging using [18F]-setoperone to quantify
cortical 5-HT2A receptors has the potential to inform pharmacological treatments for geriatric
depression and dementia. Prior reports indicate a significant normal aging effect on serotonin
5HT2A receptor (5HT2AR) binding potential. The purpose of this study was to assess the test-retest
variability of [18F]-setoperone PET with a high resolution scanner (HRRT) for measuring 5HT2AR
availability in subjects greater than 60 years old. Methods: Six healthy subjects (age range = 65–78
years) completed two [18F]-setoperone PET scans on two separate occasions 5–16 weeks apart.
Results: The average difference in the binding potential (BPND) as measured on the two occasions
in the frontal and temporal cortical regions ranged between 2 and 12%, with the lowest intraclass
correlation coefficient in anterior cingulate regions.
Conclusion:  We conclude that the test-retest variability of [18F]-setoperone PET in elderly
subjects is comparable to that of [18F]-setoperone and other 5HT2AR radiotracers in younger
subject samples.
Background
As the proportion of the aged in the population increases,
cognitive impairment and depression in older adults has
become a public health priority. Twenty-five to thirty per-
cent of nursing home residents are taking second genera-
tion antipsychotic medications [1], for which the
serotonin 2A receptor (5HT2AR) is a target of action. In
addition, selective serotonin reuptake inhibitors (SSRIs)
are first line drugs in the management of depression and
have recently been studied for the management of psycho-
logical and behavioural manifestations of dementia [2,3].
The efficacy and/or adverse effects of atypical antipsychot-
ics (e.g., risperidone [4]; and SSRIs in these contexts is
predicated upon pre- and post-synaptic effects at several
central nervous system serotonin receptors, so that the
ability to quantify serotonin receptors in vivo in older
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subjects is critical to understanding more about the mech-
anisms of action of the available medications and to
inform the development of more effective treatments.
Autoradiography findings [5-7] and radiotracer PET stud-
ies [8-15] have reported both increases and decreases in
5HT2AR in major depression in younger patients, but no
change in older depressed patients (in one study), and
decreases in Alzheimer's disease (AD). In addition to the
reported 5HT2AR reduction due to neuropsychiatric disor-
ders, there are significant declines in 5HT2AR binding in
normal aging, that are independent of disease state [8,12].
Given the decrease in 5HT2AR binding with age and dis-
ease, it is important to assess the stability of 5HT2AR meas-
urements prior to undertaking studies to measure disease
and treatment related effects for older subjects.
The radiotracers [18F]-altanserin, [11C]-MDL100,907, and
[18F]-setoperone have been used to study cortical 5HT2AR
in neurochemical PET imaging studies [12,14,16-21].
Test-retest variability of 5HT2AR measurement with [18F]-
altanserin and PET with arterial blood sampling has been
reported in several studies. Soares et al. reported high
mean intra-subject % change of 11–14% for cortical brain
areas for the ratio of specific to non-displaceable brain
uptakes and the ratio of specific brain uptake to total par-
ent plasma concentration [21]. A four compartment mode
tracer kinetic model yielded average differences of 13% or
less in regions of high receptor concentrations and 16–
20% for regions of low receptor concentrations. The
Logan graphical analysis method showed variability of
12% or less across ratios for distribution volumes and of
less than 10% for distribution volume ratios normalized
to the cerebellum [22]. The observation that radiolabelled
metabolites of [18F]-altanserin cross the blood brain bar-
rier complicates the use of the cerebellum as the input
function as opposed to arterial blood [23,24]. We used
setoperone to offer our subjects a less invasive procedure.
Kapur et al. [19] found even lower mean intra-subject per-
cent change and higher intra-class correlation coefficients
for [18F]-setoperone using the cerebellum as the input
function. This degree of reliability has been shown thus
far only in young subjects (under age 40 years) for [18F]-
setoperone [19]. We followed up on this previous work by
testing the reliability of measuring 5HT2AR in healthy eld-
erly subjects (over age 60 years) using the radioligand
[18F]-setoperone with a high resolution brain PET scanner
(HRRT). We chose to examine this reliability in areas of
the brain related to depression and dementia: prefrontal,
including the anterior cingulate gyrus, temporal, and
insular cortex.
Methods
Healthy subjects volunteered in response to advertise-
ments in the community. The inclusion criteria included:
minimum age of 60 years; independence in all activities of
daily living; and absence of any current or past psychiatric
illness, significant neurological disorder (e.g., stroke) or
diagnosis of cognitive impairment. Subjects were
excluded if they had a history of substance abuse or
dependence, unstable systemic disease, concurrent use of
psychotropic drugs including SSRIs, serotonin/norepine-
phrine reuptake inhibitor antidepressants, trazodone, sec-
ond generation antipsychotics, or contraindication to
MRI procedures. The subjects provided written informed
consent as approved by the Research Ethics Board at the
Centre for Addiction and Mental Health (CAMH).
Each of 6 subjects completed two [18F]-setoperone PET
scans separated in time by 5 to 16 weeks (specifically, 5,
5, 6, 11, 13, and 16 week intervals), in addition to a single
MRI scan of the brain for the purpose of co-registration
and exclusion of brain pathology.
MRI scanning procedure: Participants underwent stand-
ard fast spin echo T1-weighted imaging (GE Magnetom
(Milwaukee, WI) 1.5 T scanner; fast spoiled gradient echo,
time to echo = 5.3–15 msec, repetition time = 8.9–12
msec, field of view = 20 cm (three-dimensional), 256 ×
256 voxel 1.5 isotropic, number of excitations = 1) and a
proton density image (time to echo = 17, repetition time
= 6,000, field of view = 22 cm (two-dimensional), 256 ×
256, slice thickness = 2 mm, number of excitations = 2).
The T1 image was used for the region of interest (ROI)
analysis.
PET scanning procedure: The PET scanning methods have
been described previously by Mamo et al. [25] Briefly,
subjects fasted from 8 AM on the day of the PET scan until
after the study. Upon arrival at the PET Centre, the PET
procedures were reviewed with the subject. Patients were
scanned lying supine and with fixation of the head
achieved using a thermoplastic facemask (Raycast Efficast,
Orfit Industries, http://www.orfit.com), allowing for con-
sistent repositioning between the two PET scans. A cathe-
ter was then inserted into an antecubital vein for
radiotracer administration. Then, transmission scans were
acquired immediately before emission scans using a sin-
gle photon 137Cs source for attenuation correction of the
emission scans.
[18F]-setoperone was prepared by the previous published
method of Maziere et al, with [18F]-fluoride displacement
on the nitro-derivative precursor of setoperone [26].
Dynamic PET scans began immediately upon bolus injec-
tion of [18F]-setoperone (mean dose = 4.8 mCi [SD = 0.2],
mean specific activity = 115.0 mCi/μmol [SD = 975]) and
lasted for 90 minutes. A HRRT high-resolution neuro-PET
camera system (Siemens Molecular Imaging, Knoxville,
TN) was used to acquire the PET data. Emission data were
acquired in list mode and later reconstructed by filtered-
back projection to yield dynamic images in 22 framesBMC Medical Imaging 2009, 9:12 http://www.biomedcentral.com/1471-2342/9/12
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(five 1-minute and seventeen 5-minute frames). The data
were reconstructed into 207 brain sections with an
interslice distance of 1.2 mm and an in-plane resolution
of approximately 2.8 mm full width at half-maximum.
Image Analysis
The PET data were analysed using a region of interest
method described previously (Region of Mental Interest
[ROMI]) by Rusjan et al. [27]. This software, in concert
with SPM2, (i) transforms a standard brain template with
a set of predefined ROIs to match individual high-resolu-
tion MR images, (ii) refines the ROIs from the trans-
formed template based on the gray matter probability of
voxels in the individual MR images (segmentation step),
and (iii) co-registers the individual MR images to the PET
images so that the individual refined ROIs are trans-
formed to the PET image space. ROIs delineated automat-
ically with ROMI were left and right: frontal, temporal,
anterior cingulate, and insula. The ROI template is based
on the anatomical label atlas of Talairach transformed to
the standard ICBM//MNI 152 brain, which is included in
the WFU toolbox for SPM [28]. One trained investigator
(HU) visually checked ROI placement for all subjects and
judged all but one of the ROIs delineated automatically to
be accurate. The cerebellar ROI used to generate BPNDs for
the one subject was drawn manually by HU, using the
same anatomical landmarks as ROMI.
ROMI was developed after the prior study of setoperone
PET test-retest variability [19]. It affords analysis of insular
and anterior cingulate regions, which have been of inter-
est in behavioural neuroscience. e.g., [29,30]
Based on previous reports that the cerebellar binding is
not significantly displaced by 5HT2A antagonists in non-
human primates and human subjects [31,32], the cerebel-
lar cortex, excluding the vermis, was used as the reference
region. PMOD version 2.7 (PMOD Technologies, Ltd.,
Zurich, Switzerland) was used to generate time activity
curves (TAC). To determine the 5HT2 receptor binding
potential, we used the simplified reference tissue model
(SRTM). Binding potential (BPND) is defined as the ratio
of k3 to k4, where k3 and k4 are the rate constants of radio-
ligand delivery and transfer out of the specifically bound
compartment in a two-tissue compartment model [33].
Statistical Analysis
We assessed the test-retest reliability of the binding poten-
tials for each of the six ROIs automatically delineated by
ROMI (N = 6) using single measure intraclass correlation
coefficients (ICC, SPSS: Analysis: Scale: Reliability: Statis-
tics – ICC, two-way mixed effects model for consistency).
The interval between scans was factored into the Repeated
Measures analysis for ICC as a between-subjects factor. An
interval of 8 weeks or fewer was considered short; inter-
vals of 9 weeks or more (maximum 16 for this study) were
considered longer. We also examined repeatability coeffi-
cients (RC).
The RC was calculated as twice the standard deviation
(SD) of the difference between the two BPND values for
each of the ROIs from the 1st and 2nd analyses (e.g., left
frontal BPs from scans 1A and 1B) [34] Analysis of vari-
ance was performed to compare the volume of the ROIs
between the first and the second scan.
Results
Table 1 lists the mean 5HT2AR BPNDs and volumes for
each of the ROIs. Table 2 lists the percent change in mean
difference, ICC, and RC for each of the regional 5HT2AR
BPNDs.
Prefrontal, temporal, and insular cortical ROIs had high
test-retest reliability (ICCs ranging from .91 to .97). The
anterior cingulate ROIs generate low signal, approxi-
mately half that of the temporal ROIs, but this may be due
to the smaller volumes of those ROIs. Nevertheless, the
right anterior cingulate ROIs generate 2/3 the BPND of the
left, despite the right side having a larger volume. Test-
retest reliability may suffer in ROIs of smaller volume
and/or those with lowest radiotracer binding.
Both left and right anterior cingulate ROIs were less con-
sistent between scans, especially for two subjects who
showed an anterior cingulate BPND  value of zero or
unmeasurable from one but not their second PET scans.
These two subjects consisted of one 76 year old woman
and one 63 year old man, with between-PET intervals of 5
and 6 weeks, respectively. When data from the two sub-
jects were excluded from the analysis of anterior cingulate
measures, the new % change in left and right mean differ-
ence (2.1% and 5.5%, respectively), RC (.03 and .05,
respectively) were lowered to the range of other ROIs for
the group. The slight improvement in the right anterior
cingulate ICC of .71 to .78 was not statistically significant
(p > 0.05).
All subjects in this study were right-handed. This may
account for the asymmetry of BPND in anterior cingulate
ROIs to some degree.
The deviation from one scan to the second was not signif-
icantly related to the short vs. longer time interval
between scans (F[df = 1,5] = 118.92, p = .07).
Discussion
The BPNDs for frontal and temporal ROIs in this report is
comparable to previously published figures: Meltzer et al.
found uncorrected BPNDs of 0.53–0.59, and Blin et al.
reported that most BPNDs were near 0.43. These figures fallBMC Medical Imaging 2009, 9:12 http://www.biomedcentral.com/1471-2342/9/12
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within our range of 0.33 – 0.6, but the right anterior cin-
gulate BPND in this study seemed to dip close to measures
of BPNDs from anterior cingulate ROIs in Blin's study on
subjects with Alzheimer's disease. Although we excluded
subjects who were cognitively impaired, it is possible that
the two subjects with the lowest anterior cingulate BPNDs
are in a pre-symptomatic phase of Alzheimer's disease.
Another consideration for these results is the relative
impact of scan resolution on ROIs of differing sizes and
shapes [35,36]. Kessler et al. suggest that a ROI with diam-
eter of at least 2.7 × FWHM is the smallest volume to
obtain the full radioactivity recovery with inter-slice dis-
tance of no more than 1/2 × FWHM on the z axis. We used
an HRRT scanner with FWHM of 2.8 mm and inter-slice
Table 1: Mean binding potentials (BPND) and standard deviations (SD) for repeated setoperone PET scans (N = 6).
Left-sided ROIs Mean BPND (SD) *Mean volume of ROI (SD) in mm3 Right-sided ROIs Mean BPND (SD)
0.52 8070 0.47 8641
Scan 1 frontal (0.28) (987) Scan 1 frontal (0.25) (999)
0.53 8074 0.49 8661
Scan 2 frontal (0.27) (994) Scan 2 frontal (0.24) (1005)
0.60 8133 0.58 8221
Scan 1 temporal (0.37) (1082) Scan 1 temporal (0.39) (755)
0.58 8115 0.59 8231
Scan 2 temporal (0.33) (1057) Scan 2 temporal (0.34) (774)
0.33 741 0.22 762
Scan 1 anterior cingulate (0.34) (138) Scan 1 anterior cingulate (0.25) (135)
0.36 735 0.25 753
Scan 2 anterior cingulate (0.24) (140) Scan 2 anterior cingulate (0.20) (123)
0.45 3649 14221
**Scan 1 average insula (0.31) (794) Scan 1 cerebellum Reference ROI (1821)
0.48 3628 14188
**Scan 2 average insula (0.29) (783) Scan 2 cerebellum Reference ROI (1799)
* Comparison between ROIs' volume (scan 1 vs. scan 2): F[3,8] = 0.108, p = 0.99.
**ROMI generates the insular region of interest as an average of the left and right sides.
Table 2: Mean differences, intraclass correlation coefficients (ICC), and repeatability coefficients (RC) for [18F]-setoperone binding 
potential test-retest. 
Left Right Average
Region of Interest Mean diff ICC [CI] RC Mean diff ICC [CI] RC ICC [CI] RC
Temporal lobe 3.3% 0.97 0.05 1.7% 0.94 0.02 0.96 0.01
[.83, 1.0] [.66, .99] [.72, .99]
Frontal lobe 1.9% 0.94 0.03 4.1% 0.91 0.05 0.93 0.04
[.69, .99] [.53, .99] [.43, .96]
Anterior cingulate 8.3% 0.69 0.06 12.0% 0.71 0.06 .76 0.06
[-.09, .95] [-.05, .96] [.01, .97]
Insula 0.97
- - - - - - [.85, 1.0] 0.06
Average 0.87 0.05 0.85 0.04 0.91 0.04
All p values for ICC < .05.BMC Medical Imaging 2009, 9:12 http://www.biomedcentral.com/1471-2342/9/12
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distance of 1.2 mm. This FWHM is ~4 times lower than
the diameter of the anterior cingulate, which was the
smallest ROI studied, volume = 740 mm3 (assuming a
sphere with diameter 11.2 mm). Thus, our scanner resolu-
tion should be able to handle all of the ROIs included in
this study.
This study shows that cortical 5HT2AR as measured with
[18F]-setoperone PET and using non-invasive modelling
methodology is reproducible to the same extent observed
in other test-rest studies of younger subjects. The level of
reliability paralleled the prior study by Kapur et al. show-
ing high ICCs (.96–.97) for frontal and temporal regions
in subjects aged 21–35 years [19]. An age-related decrease
in cortical 5HT2AR (including the anterior cingulate) has
been observed on other PET studies of the 5HT2AR [8,37].
The low signal in the anterior cingulate in the present
study suggests that partial volume correction may be nec-
essary, particularly for between-group comparisons.
The cortical BPNDs observed in older subjects were lower
than BPNDs among younger controls reported previously
in the literature by studies that did not complete test-retest
scans [8,11,14,37-39]. Our frontal BPNDs were approxi-
mately 25–27% of the average frontal and temporal BPs
reported by Kapur et al. in subjects aged 21–35 and 20%
of those reported for the subset of 20–25 year old subjects
in the study by Lewis et al. using [18F]-setoperone and the
same modelling with SRTM but imaging with the lower
resolution PET scanner (0.5 vs. 2.5 mm) [20]. Extrapola-
tion into the aged population using the 6%-per-decade
decline in altanserin binding reported by Adams et al. [40]
could result in BP at roughly 20–25% that of younger sub-
jects, but the average 1.5%-per-decade decline in setoper-
one binding reported by Blin et al. [8] would extrapolate
to a less drastic decline than the low BPNDs reported in the
current study. Nevertheless, our BPNDs are not likely to
have resulted merely from a quantification approach that
differed from Kapur et al. [19].
To our knowledge, this is the first study to report test-
retest variability of 5HT2AR BPs in health control subjects
over age 60. This is also one of the few reported test-retest
studies conducted in an HRRT scanner. The small sample
size used in this study may be a limitation and should be
considered in interpreting the results. Power analyses for
standard beta level = 0.2 were conducted using required
sample size  , where SD = standard devia-
tion and d = mean difference of BPs from the right tempo-
ral ROI, which had the highest ICC in this study. Whereas
within-subject differences of 10% or more could be
detected with a sample size of 8, between-group differ-
ences of 25% or more would require a sample size of 28
subjects in each comparison group. This is a significant
increase from the sample size of 12–15 per group extrap-
olated in Kapur et al.'s previous study in healthy young
controls [19]. The sample size in studies seeking between-
group differences in 5HT2AR BP was likely driven up by
the large between-subjects standard deviation among
healthy elderly.
Conclusion
There is high test-retest reliability for healthy elderly sub-
jects using setoperone PET imaging, yet clinical research-
ers must take high intersubject variability for this
population into account when designing studies of the
role of 5HT2AR as a biomarker for exploring serotonergic
function in elderly patients with depression or dementia.
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